CMPX biotech catalysts & pipeline

COMPASS THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

tovecimig — FDA meeting

this quarter

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year.

Source filing

CTX-10726 — Initial data

The first patients in the Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) have been dosed and the study is actively enrolling, with initial data expected in Q4.

Source filing

CTX-8371 — Initial data

Q4 2026

Additional data from the cohort expansions are expected in Q4 2026.

Source filing

tovecimig — NDA/BLA submission

Q4 26

Q4 26: Submit BLA

Source filing

tovecimig — Conference presentation

Oct 23–Oct 27

Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.

Source filing

Explore the free biotech catalyst calendar